ClinicalTrials.gg
RecruitingNCT06994689MetriquadUpdated Jan 21, 2026

Clinimetric Properties of Muscle Mass and Stiffness Measurements of the Quadriceps in Patients With COPD

An observational study in COPD and Quadriceps Muscle Atrophy, sponsored by Groupe Hospitalier du Havre. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Groupe Hospitalier du Havre · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre — 3 open to participants now, 3 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Groupe Hospitalier du Havre.

Started
2025
the only one that year
Observational
5 of 10
2 open now
Registered
8th of 10
by date

Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre, this one is the only one that started in 2025, is one of 5 observational ones, and was the 8th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre, or all of them as a file.
02

Study summary

A large amount of patients with COPD suffer from muscle dysfunction characterized by losses of muscle mass and strength. Studies have shown an association between a loss of quadriceps muscle mass and premature death.

This study aims to investigate the clinimetric properties of a simple quadriceps perimetry and ShearWave elastography to improve the monitoring of skeletal muscle function in patients with COPD.

Read the detailed description

Muscle dysfunction in COPD is characterized by reduced skeletal muscle mass and strength, particularly in the lower limbs. These systemic consequences of COPD play a key role in the course of these patients, through their impact on functional status, quality of life and increased mortality. Early detection and monitoring of muscular status in these patients could help improve management and limit the consequences of the disease.

Numerous studies show that variation in quadriceps mass has a significant relationship with premature mortality in this disease. The use of an indirect but simple and affordable measure: perimetric tape-measurement of thigh circumference, could help monitor quadriceps muscle mass in these patients on a regular and cost-effective basis. However, the clinimetric properties (validity, reliability, response to treatment) of this measurement need to be assessed to clarify its relevance.

On the other hand, ShearWave ® elastography (SWE) is a new method of measuring quadriceps stiffness. This measurement could provide additional information on muscle quality compared with conventional measures of strength or muscle trophicity. The potential added value of SWE ® for COPD patients has not yet been investigated. This tool would provide more precise indications of the state of the quadriceps, with the aim of improving the management of this pathology.

03

Conditions studied

  • COPD
  • Quadriceps Muscle Atrophy

Keywords

  • Clinimetric properties
  • Muscle mass
  • Muscle strength
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

COPD patients completing a PR programme for 5 weeks

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients
  • Adults (>18 years old)
  • Patients starting a pulmonary rehabilitation (PR) programme

Exclusion criteria

Exclusion Criteria:

  • Patients included in other research protocol
  • Minors or under guardianship
  • Pregnancy
  • Patients with lower limb amputation or history of neuromuscular disease
  • Cardiovascular contradications for PR
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testPerimetry and ShearWave measurement of the quadriceps muscle before and after a pulmonary rehabilitation (PR) programme

    Patients will undergo a pulmonary rehabilitation (PR) programme. On day 1, perimetry and ShearWave measurements of the quadriceps muscle will be provided. Supplementary assessments of quadriceps thickness, quadriceps strength with a handheld dynamometry, lean body mass (bioelectrical impedance), constant work-rate endurance test and HAD questionnaire will also be provided on day 1. The same measurements and questionnaire will be provided on the last day of the patient in the PR programme.

    Also known as: Functional exercice capacity, Quality of life, Bioelectrical impedance, Quadriceps thickness, Quadriceps strength : maximal voluntary contraction

06

What researchers measure

Primary outcomes

  1. Perimetry of the quadriceps

    Thigh circumference measured by a tape

    Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)

  2. Quadriceps stiffness

    ShearWave elastography of the quadriceps muscle

    Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)

Secondary outcomes

  1. Lean body mass

    measured by bioelectrical impedance

    Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)

  2. Functional exercise capacity

    measured as the endurance time during a constant load endurance test using a cycloergometer or a treadmill

    Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)

  3. Health-Related Quality of Life

    measured by quality of life questionnaire (hospital anxiety and depression scale (HAD))

    Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)

  4. Quadriceps thickness

    measured by ultrasonography

    Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)

  5. Quadriceps strength

    measure of maximal voluntary contraction with handheld dynamometry

    Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol

Time frame: Beginning after publication and ending 60 months following article publication.

Access criteria: For individual participant data meta-analysis. Proposals should be directed to yann.combret@gmail.com. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 16 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
May 29, 2025
StartActual
May 30, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06994689
Lead sponsor
Groupe Hospitalier du Havre
Responsible party
Sponsor
First posted
May 29, 2025
Start date
May 30, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jan 21, 2026

Study contacts

Claire Dubois, PT
Contact
claire.dubois@ch-havre.fr
(+33)630039745
Yann Combret, PhD
Contact
yann.combret@ch-havre.fr
(+33)686327255

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion